26.09.2016 LANXESS Aktiengesellschaft  DE0005470405

DGAP-Adhoc: LANXESS signs contract to acquire Chemtura

LANXESS Aktiengesellschaft / Key word(s): Takeover 26.09.2016 00:24 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Cologne - Specialty chemicals company LANXESS has signed a contract to take over the US-based specialty chemicals company Chemtura Corporation. Chemtura is one of the major global providers of high-quality flame retardant- and lubricant additives. LANXESS is offering all cash consideration of USD 33.50 per share. For the transaction with an enterprise value of around EUR 2.4 billion LANXESS has secured bridge financing. The bridge financing will quickly be refinanced via senior bonds and a hybrid bond. Furthermore, LANXESS will use existing liquidity for financing. Closing is subject to approval by Chemtura shareholders, any required regulatory approvals and certain other customary closing conditions. Closing of the transaction is anticipated mid-2017. Chemtura employs worldwide approximately 2,500 employees and has 20 sites in 11 countries. The company's headquarters are in Philadelphia, Pennsylvania. The stock market listed company reported sales of around EUR 1.5 billion in the last four quarters and EBITDA pre exceptionals of approximately EUR 245 million. Around 45 percent of its turnover are generated in North America. In addition to additives, the portfolio also comprised urethanes and organometallics. A combination of both companies would materially expand LANXESS' business activities in additives for lubricants and flame retardants. Against the backdrop of the acquisition, the announced share buy-back of around EUR 200 million will not be pursued further. Cologne, September 25, 2016 Forward-Looking Statements This company release contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document. Important Additional Information This company release relates to the proposed acquisition of Chemtura Corp. by LANXESS AG. The information included herein is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities, nor a solicitation of any vote or approval. No public market exists for the securities of LANXESS AG in the United States. The proposed acquisition will be submitted to the stockholders of Chemtura Corp. for their consideration. In connection therewith, Chemtura Corp. intends to file a proxy statement with the U.S. Securities and Exchange Commission ("SEC") and mail such proxy statement to its stockholders of record. BEFORE MAKING ANY VOTING OR ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders will be able to obtain free copies of the proxy statement, any amendments or supplements thereto and other documents containing important information about Chemtura Corp., once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Chemtura Corp. will be available free of charge on Chemtura Corp.'s website at http://investor.chemtura.com under the heading "Financials & Filings". Stockholders of Chemtura Corp. may also obtain a free copy of the definitive proxy statement by contacting Chemtura Corp.'s Investor Relations Department at +1 (203) 573-2153. 26.09.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: LANXESS Aktiengesellschaft Kennedyplatz 1 50569 Köln Germany Phone: +49 (0)221 8885-0 Fax: +49 (0)221 8885-4944 E-mail: [email protected] Internet: www.lanxess.com ISIN: DE0005470405 WKN: 547040 Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 7.699,00 6.530,00 7.197,00 6.802,00 6.104,00 7.557,00 8.088,00
EBITDA1,2 995,00 709,00 935,00 910,00 757,00 863,00 826,00
EBITDA-Marge3 12,92 10,86 12,99 13,38 12,40 11,42 10,21
EBIT1,4 464,00 299,00 504,00 407,00 253,00 350,00 280,00
EBIT-Marge5 6,03 4,58 7,00 5,98 4,14 4,63 3,46
Jahresüberschuss1 195,00 124,00 523,00 191,00 902,00 267,00 251,00
Netto-Marge6 2,53 1,90 7,27 2,81 14,78 3,53 3,10
Cashflow1,7 689,00 868,00 586,00 643,00 585,00 407,00 159,00
Ergebnis je Aktie8 2,10 0,95 4,71 2,32 10,22 3,09 2,90
Dividende8 0,70 0,80 0,90 0,95 1,00 1,05 1,05
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

WKN Kurs in € Einschätzung Börsenwert in Mio. €
547040 34,980 Halten 3.020,39
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
11,28 17,21 0,65 11,19
0,70 19,00 0,37 8,27
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
1,05 1,05 3,00 24.05.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
10.05.2023 04.08.2023 08.11.2023 15.03.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-19,29% -7,12% -7,21% -17,83%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu LANXESS Aktiengesellschaft  ISIN: DE0005470405 können Sie bei EQS abrufen

Chemie , 547040 , LXS , XETR:LXS